Abstract
The evolution of Mycobacterium tuberculosis presents several challenges for public health. HIV and resistance to antimycobacterial medications have evolutionary implications for how Mycobacterium tuberculosis will evolve, as these factors influence the host environment and transmission dynamics of tuberculosis strains. We present an evolutionary invasion analysis of tuberculosis that characterizes the direction of tuberculosis evolution in the context of different natural and human-driven selective pressures, including changes in tuberculosis treatment and HIV prevalence. We find that the evolution of tuberculosis virulence can be affected by treatment success rates, the relative transmissibility of emerging strains, the rate of reactivation from latency among hosts, and the life expectancy of hosts. We find that the virulence of tuberculosis strains may also increase as a consequence of rising HIV prevalence, requiring faster case detection strategies in areas where the epidemics of HIV and tuberculosis collide.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Anderson, R.M., May, R.M., 1991. Infectious Diseases of Humans: Dynamics and Control. Oxford University Press, London.
Basu, S., , 2007. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 370(9597), 1500–1507.
Blower, S.M., Chou, T., 2004. Modeling the emergence of the ‘hot zones’: tuberculosis and the amplification dynamics of drug resistance. Nat. Med. 10(10), 1111–1116.
Blower, S.M., Gerberding, J.L., 1998. Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: a theoretical framework. J. Mol. Med. 76(9), 624–636.
Blower, S.M., , 1995. The intrinsic transmission dynamics of tuberculosis epidemics. Nat. Med. 1(8), 815–821.
Boots, M., Sasaki, A., 1999. ‘Small worlds’ and the evolution of virulence: infection occurs locally and at a distance. Proc. Biol. Sci. 266, 1933–1938.
Bremerman, H.J., Thieme, H.R., 1989. A competitive-exclusion principle for pathogen virulence. J. Math. Biol. 27, 179–190.
Castro, K.G., Dooley, S.W., 1993. Mycobacterium tuberculosis transmission in healthcare settings: is it influenced by coinfection with human immunodeficiency virus? Infect. Control. Hosp. Epidemiol. 14(2), 65–66.
Cohen, T., Murray, M., 2004. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat. Med. 10(10), 1117–1121.
Cohen, T. et al., 2006. Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission. J. R. Soc. Interface.
Corbett, E.L., , 2006. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 367(9514), 926–937.
Crofton, J., Horne, N., Miller, F., 1999. Pulmonary tuberculosis in adults. In: Clinical Tuberculosis. MacMillan, London.
Cruciani, M., , 2001. The impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: a meta-analysis. Clin. Infect. Dis. 33(11), 1922–1930.
Daley, C.L., , 1992. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N. Engl. J. Med. 326(4), 231–235.
Di Perri, G., , 1989. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 2(8678–8679), 1502–1504.
Dye, C., Espinal, M.A., 2001. Will tuberculosis become resistant to all antibiotics? Proc. Biol. Sci. 268(1462), 45–52.
Dye, C., Williams, B.G., 2000. Criteria for the control of drug-resistant tuberculosis. Proc. Natl. Acad. Sci. USA 97(14), 8180–8185.
Dye, C., , 1998. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 352(9144), 1886–1891.
Dye, C., , 2002. Erasing the world’s slow stain: strategies to beat multidrug-resistant tuberculosis. Science 295(5562), 2042–2046.
Ebert, D., Bull, J.J., 2003. Challenging the trade-off model for the evolution of virulence: is virulence management feasible? Trends Microbiol. 11(1), 15–20.
ECA, 2006. Beijing/W genotype mycobacterium tuberculosis and drug resistance. Emerg. Infect. Dis. 12(5), 736–743.
Edlin, B.R., , 1992. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 326(23), 1514–1521.
Ernst, J.D., Trevejo-Nunez, G., Banaiee, N., 2007. Genomics and the evolution, pathogenesis, and diagnosis of tuberculosis. J. Clin. Invest. 117(7), 1738–1745.
Escombe, A.R., , 2007. The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air sampling model. Clin. Infect. Dis. 44(10), 1349–1357.
Eshel, I., 1983. Evolutionary and continuous stability. J. Theor. Biol. 103, 99–111.
Feng, Z., Castillo-Chavez, C., Capurro, A.F., 2000. A model for tuberculosis with exogenous reinfection. Theor. Popul. Biol. 57(3), 235–247.
Friedland, G., 2007. Tuberculosis, drug resistance and HIV/AIDS: a triple threat. Curr. Infect. Dis. Rep. 9(3), 252–261.
Friedland, G., Churchyard, G.J., Nardell, E., 2007. Tuberculosis and HIV coinfection: current state of knowledge and research priorities. J. Infect. Dis. 196(1), S1–S3.
Gandhi, N.R., , 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368(9547), 1575–1580.
Githui, W.A., , 2004. Identification of MDR-TB Beijing/W and other mycobacterium tuberculosis genotypes in Nairobi. Kenya. Int. J. Tuberc. Lung. Dis. 8(3), 352–360.
Health Systems Trust, 2007. HIV Prevalence. HST, Durban.
Keeler, E., , 2006. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 444(1), 49–57.
Keeling, M.J., Rohani, P., 2007. Modeling Infectious Diseases in Humans and Animals. Princeton University Press, Princeton.
Lan, N.T., , 2003. Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse. Vietnam. Emerg. Infect. Dis. 9(12), 1633–1635.
Lawn, S.D. et al., 2007. Early mortality among patients with HIV-associated TB in Africa: implications for the time to initiate ART. In: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles.
Levin, B.R., 1996. The evolution and maintenance of virulence in microparasites. Emerg. Infect. Dis. 2(2), 93–102.
Lipsitch, M., Murray, M.B., 2003. Multiple equilibria: tuberculosis transmission require unrealistic assumptions. Theor. Popul. Biol. 63(2), 169–170.
Mann, N.H., , 2003. Marine ecosystems: bacterial photosynthesis genes in a virus. Nature 424(6950), 741.
Moore, D.A., , 2006. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N. Engl. J. Med. 355(15), 1539–1550.
Otto, S.P., Day, T., 2007. A Biologist’s Guide to Mathematical Modeling in Ecology and Evolution. Princeton University Press, Princeton.
Pillay, V., Sturm, A.W., 2007. Evolution of the extensively dRUG-resistant F15/LAM4/KZN strain of mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis. 45(11), 1409–1414.
Sherman, D.R., , 1996. Compensatory ahpC gene expression in isoniazid-resistant mycobacterium tuberculosis. Science 272(5268), 1641–1643.
Small, P.M., , 1993. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N. Engl. J. Med. 328(16), 1137–1144.
Smith, J.M., Price, G.R., 1973. The logic of animal conflict. Nature 246, 15–18.
Special Programme for Tropical Diseases Research, 2006. Diagnostics for Tuberculosis: Global Demand and Market Potential. WHO, Paris.
van den Driessche, P., Watmough, J., 2002. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math. Biosci. 180, 29–48.
Williams, B.G., Dye, C., 2003. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 301(5639), 1535–1537.
Williams, B.G., , 2005. The impact of HIV/AIDS on the control of tuberculosis in India. Proc. Natl. Acad. Sci. USA 102(27), 9619–9624.
World Health Organization, 2005. The Impact of HIV on TB in Africa. WHO, Paris.
World Health Organization, 2006. Progress on Global Access to HIV Antiretroviral Therapy: A Report on “3 by 5” and beyond. WHO, Paris.
World Health Organization, 2007a. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO, Paris.
World Health Organization, 2007b. Global Tuberculosis Control—Surveillance, Planning, Financing. WHO, Paris.
Wright, S., 1931. Evolution in Mendelian populations. Genetics 16, 97–159.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Basu, S., Galvani, A.P. The Evolution of Tuberculosis Virulence. Bull. Math. Biol. 71, 1073–1088 (2009). https://doi.org/10.1007/s11538-009-9394-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11538-009-9394-x